Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001214659-24-016051
Filing Date
2024-09-04
Accepted
2024-09-04 17:40:49
Documents
1
Period of Report
2024-08-01

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-66911.html 4  
1 PRIMARY DOCUMENT marketforms-66911.xml 4 34838
  Complete submission text file 0001214659-24-016051.txt   36263
Mailing Address 1207 17TH AVENUE SUITE 103 NASHVILLE TN 37212
Business Address
KAZIMI A J (Reporting) CIK: 0001075050 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 241278503

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)